Group 1 - Xenon Pharmaceuticals Inc. is conducting phase 3 clinical trials for its lead asset azetukalner (XEN1101), targeting focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) [1] - The company is also involved in a phase 3 trial named X-NOVA2 [1] Group 2 - The Total Pharma Tracker offers tools for DIY investors, including a software for entering tickers to access extensive curated research material [3] - In-house experts provide hands-on support to identify the best investable stocks, along with buy/sell strategies and alerts [3] - A free trial is available for investors to explore the tools and services offered by the company [3]